Cytovale
PrivateLast Round
Series D
Oct 10, 2024
Est. Valuation
$32.25M
Total Funding Raised
$226.59M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Cytovale is a biotechnology company that develops innovative diagnostic technologies using cell mechanics and machine learning to enable the early detection of sepsis.
Sector
Healthcare & Life Sciences
Verticals
Medical Devices, Biotechnology, Healthcare Analytics
Business Model
B2B
Customer Profile
Usage-Based SaaS, Hardware Sales
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Cytovale Comparables
Compare Cytovale with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Prenosis | 81% | |
| Inflammatix | 81% | |
| ASEP Medical Holdings Inc. | 78% |
Cytovale Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series D | Oct 10, 2024 | ||||
| Series C | Nov 15, 2023 | ||||
| Grant | Feb 8, 2022 | ||||
| Grant | May 19, 2020 | ||||
| Series B Extension | Oct 30, 2019 | ||||
Grant | Sep 28, 2019 |
Key People
Founding team and executive leadership
Cytovale Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pactolus Ventures | Series B, Series B Extension |
| CPP Investments | Series D |
| Dolby Family Ventures | Seed, Series A |
| IT-Farm Corporation | Series A |
| Thiel Foundation | Seed, Series A |
| Creative Ventures | Grant |
| Baidu Ventures | Series B, Series B Extension |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 7, 2026
Eric Khairy appointed as the new Chief Marketing Officer.
- Mar 1, 2025
Dave Vort appointed as Chief Commercial Officer.
Recent news
Latest coverage and updates
- partners_withSep 23, 2026
Cytovale partnered with Fmolhs on Apr 1st '23.
Cytovale Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Cytovale's valuation, stock price, and market status.
Is CytoVale a public or private company?
CytoVale is a private company.
What is the current stock price of CytoVale?
CytoVale is a private company with no public stock price. No recent secondary market data is available.
How much is CytoVale worth (valuation)?
CytoVale's valuation is estimated at $32.3M based on funding round data.
Can I buy CytoVale stock?
CytoVale shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was CytoVale's last funding round?
CytoVale's most recent funding round was Series D on December 22, 2017.
Who are the main investors in CytoVale?
Key investors in CytoVale include Norwest Venture Partners, Breakout Ventures, Blackhorn Ventures, Sands Capital.
Will CytoVale IPO soon?
No public IPO plans have been announced for CytoVale.
How can I track CytoVale secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor CytoVale's secondary market activity and sign up for updates.